The Xpert Omni platform will launch in 2016 running Cepheid test cartridges on a compact battery-operated device that is anticipated to cost less than $3,000.
The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.
The developers of the method are now using the ddPCR approach to create and test assays for early colon cancer detection.
The firm saw 24 percent growth in commercial clinical reagents revenues, while clinical systems revenue was down 23 percent.
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.